Identification and assessment of new biomarkers for colorectal cancer with serum N-glycan profiling

Cancer

Volumn 118, Issue 3, 2012, Pages 639-650

  Zhao, Yun Peng ^a   Ruan, Can Ping ^b   Wang, Hao ^b   Hu, Zhi Qian ^b   Fang, Meng ^a   Gu, Xing ^a   Ji, Jun ^a   Zhao, Jin Yan ^a   Gao, Chun Fang ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

biomarker; colorectal cancer; diagnostic model; fucosylation; N glycan profiling

Indexed keywords

BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN; DNA; FUCOSE; FUCOSYLTRANSFERASE; GLYCAN;

ADULT; ANALYTIC METHOD; ARTICLE; CANCER PATIENT; COHORT ANALYSIS; COLORECTAL ADENOMA; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DNA MODIFICATION; DNA SEQUENCER ASSISTED FLUROPHORE ASSISTED CARBOHYDRATE ELECTROPHORESIS; FEMALE; FOLLOW UP; FUCOSYLATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MOLECULAR MECHANICS; NON INVASIVE MEASUREMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR DIFFERENTIATION;

ADENOMA; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LECTINS; MALE; MIDDLE AGED; POLYSACCHARIDES; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84856218833     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26342     Document Type: Article

References (29)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55: 74-108.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008; 58: 71-96.
3. Sturgeon CM, Duffy MJ, Stenman UH, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers [serial online]. Clin Chem. 2008; 54: e11-e79.
4. Levy M, Visokai V, Lipska L, et al. Tumor markers in staging and prognosis of colorectal carcinoma. Neoplasma. 2008; 55: 138-142.
5. Duffy MJ, van Dalen A, Haglund C, et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer. 2007; 43: 1348-1360.
6. Koretz RL,. Once-only flexible sigmoidoscopy screening for colorectal cancer may not reduce colorectal cancer incidence or mortality [serial online]. Evid Based Med. 2009; 14: 171.
7. Ravindranath MH, Yesowitch P, Sumobay C, et al. Glycoimmunomics of human cancer: current concepts and future perspectives. Future Oncol. 2007; 3: 201-214.
8. Kobata A, Amano J,. Altered glycosylation of proteins produced by malignant cells, and application for the diagnosis and immunotherapy of tumors. Immunol Cell Biol. 2005; 83: 429-439.
9. Mungul A, Cooper L, Brockhausen I, et al. Sialylated core 1 based O-linked glycans enhance the growth rate of mammary carcinoma cells in MUC1 transgenic mice. Int J Oncol. 2004; 25: 937-943.
10. Arnold JN, Saldova R, Hamid UM, et al. Evaluation of the serum N-linked glycome for the diagnosis of cancer and chronic inflammation. Proteomics. 2008; 8: 3284-3293.
11. Okuyama N, Ide Y, Nakano M, et al. Fucosylated haptoglobin is a novel marker for pancreatic cancer: a detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation. Int J Cancer. 2006; 118: 2803-2808.
12. Noda K, Miyoshi E, Uozumi N, et al. Gene expression of alpha1-6 fucosyltransferase in human hepatoma tissues: a possible implication for increased fucosylation of alpha-fetoprotein. Hepatology. 1998; 28: 944-952.
13. Li D, Mallory T, Satomura S,. AFP-L3: a new generation of tumor marker for hepatocellular carcinoma. Clin Chim Acta. 2001; 313: 15-19.
14. Fang M, Zhao YP, Zhou FG, et al. N-glycan based models improve diagnostic efficacies in HBV-related hepatocellular carcinoma. Int J Cancer. 2010; 127: 148-159.
15. Dukes CE,. The surgical pathology of rectal cancer. Am J Surg. 1950; 79: 66-71.
16. Callewaert N, Van Vlierberghe H, Van Hecke A, et al. Noninvasive diagnosis of liver cirrhosis using DNA-sequencer based total serum protein glycomics. Nat Med. 2004; 10: 429-434.
17. Liu XE, Desmyter L, Gao CF, et al. N-glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus. Hepatology. 2007; 46: 1426-1435.
18. Kumar DM, Thota B, Shinde SV, et al. Proteomic identification of haptoglobin α2 as a glioblastoma serum biomarker: implications in cancer cell migration and tumor growth. J Proteome Res. 2010; 9: 5557-5567.
19. Gravel P, Walzer C, Aubry C, et al. New alterations of serum glycoproteins in alcoholic and cirrhotic patients revealed by high resolution 2-dimensional gel electrophoresis. Biochem Biophys Res Commun. 1996; 220: 78-85.
20. Turnbull JE, Field RA,. Emerging glycomics technologies. Nat Chem Biol. 2007; 3: 74-77.
21. Miyamoto S,. Clinical applications of glycomic approaches for the detection of cancer and other diseases. Curr Opin Mol Ther. 2006; 8: 507-513.
22. Morelle W, Michalski JC,. Glycomics and mass spectrometry. Curr Pharm Des. 2005; 11: 2615-2645.
23. Aoyagi Y, Saitoh A, Suzuki Y, et al. Fucosylation index of alpha-fetoprotein, a possible aid in the early recognition of hepatocellular carcinoma in patients with cirrhosis. Hepatology. 1993; 17: 50-52.
24. Miyoshi E, Moriwaki K, Nakagawa T,. Biological function of fucosylation in cancer biology. J Biochem. 2008; 143: 725-729.
25. Saitoh O, Wang WC, Lotan R, et al. Differential glycosylation and cell surface expression of lysosomal membrane glycoproteins in sublines of a human colon cancer exhibiting distinct metastatic potentials. J Biol Chem. 1992; 267: 5700-5711.
26. Szajda SD, Snarska J, Borzym-Kluczyk M, et al. Activity of β-galactosidase and α-mannosidase in the serum of patients with colon adenocarcinoma, Contemporary Oncology. 2007; 11: 64-66.
27. Szajda SD, Snarska J, Puchalski Z, et al. Lysosomal exoglycosidases in serum and urine of patients with colon adenocarcinoma. Hepatogastroenterology. 2008; 55: 921-925.
28. Ayude D, Paez De La Cadena M, Martinez-Zorzano VS, et al. Preoperative serum alpha-L-fucosidase activity as a prognostic marker in colorectal cancer. Oncology. 2003; 64: 36-45.
29. Pinho SS, Reis CA, Paredes J, et al. The role of N- acetylglucosaminyltransferase III and V in the post-transcriptional modifications of E-cadherin. Hum Mol Genet. 2009; 18: 2599-2608.